Exelixis, Inc. (NASDAQ:EXEL) Holdings Lowered by Xponance Inc.

Xponance Inc. trimmed its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 5.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 59,484 shares of the biotechnology company’s stock after selling 3,269 shares during the period. Xponance Inc.’s holdings in Exelixis were worth $1,337,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of EXEL. LSV Asset Management raised its position in Exelixis by 1,651.4% during the first quarter. LSV Asset Management now owns 2,774,707 shares of the biotechnology company’s stock valued at $65,844,000 after buying an additional 2,616,278 shares during the period. Los Angeles Capital Management LLC raised its position in Exelixis by 948.3% during the first quarter. Los Angeles Capital Management LLC now owns 2,454,277 shares of the biotechnology company’s stock valued at $58,240,000 after buying an additional 2,220,150 shares during the period. True Wealth Design LLC acquired a new position in Exelixis during the fourth quarter valued at $828,000. Intech Investment Management LLC raised its position in Exelixis by 155.8% during the first quarter. Intech Investment Management LLC now owns 100,039 shares of the biotechnology company’s stock valued at $2,374,000 after buying an additional 60,925 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in Exelixis during the first quarter valued at $1,281,000. 85.27% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Dana Aftab sold 95,000 shares of Exelixis stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the sale, the executive vice president now owns 520,990 shares of the company’s stock, valued at approximately $13,024,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Dana Aftab sold 95,000 shares of Exelixis stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the sale, the executive vice president now owns 520,990 shares of the company’s stock, valued at approximately $13,024,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jeffrey Hessekiel sold 20,000 shares of Exelixis stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.79, for a total value of $515,800.00. Following the sale, the executive vice president now directly owns 630,325 shares in the company, valued at approximately $16,256,081.75. The disclosure for this sale can be found here. Insiders have sold a total of 327,858 shares of company stock valued at $8,640,129 in the last three months. Company insiders own 2.85% of the company’s stock.

Wall Street Analyst Weigh In

EXEL has been the topic of several research reports. Truist Financial reaffirmed a “buy” rating and issued a $33.00 target price (up from $32.00) on shares of Exelixis in a research report on Thursday, August 8th. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 target price on shares of Exelixis in a research report on Tuesday, July 30th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research report on Wednesday, September 18th. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $27.00 target price on shares of Exelixis in a research report on Thursday. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.67.

Exelixis Stock Down 1.1 %

Shares of NASDAQ EXEL opened at $25.96 on Friday. The business’s 50 day moving average is $25.56 and its two-hundred day moving average is $23.48. The company has a market cap of $7.41 billion, a P/E ratio of 40.56, a P/E/G ratio of 0.56 and a beta of 0.54. Exelixis, Inc. has a 12 month low of $18.64 and a 12 month high of $27.83.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.31 by $0.44. The company had revenue of $637.18 million for the quarter, compared to the consensus estimate of $468.21 million. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. Sell-side analysts expect that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.